Related Experiment Video
Updated: Aug 23, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line
Mark D Hjelmeland1, Anita B Hjelmeland, Sith Sathornsumetee
1Division of Neurology, Duke University Medical Center, P.O. Box 2900, Durham, NC 27710, USA.
Abstract:
Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that promotes malignant glioma invasion, angiogenesis, and immunosuppression. Antisense oligonucleotide suppression of TGF-beta(2) ligand expression has shown promise in preclinical and clinical studies but at least two ligands mediate the effects of TGF-beta in gliomas. Therefore, we examined the effects of SB-431542, a novel, small molecule inhibitor of the type I TGF-beta receptor, on a panel of human malignant glioma cell lines. SB-431542 blocked the phosphorylation and nuclear translocation of the SMADs, intracellular mediators of TGF-beta signaling, with decreased TGF-beta-mediated transcription. Furthermore, SB-431542 inhibited the expression of two critical effectors of TGF-beta-vascular endothelial growth factor and plasminogen activator inhibitor-1. SB-431542 treatment of glioma cultures inhibited proliferation, TGF-beta-mediated morphologic changes, and cellular motility. Together, our results suggest that small molecule inhibitors of TGF-beta receptors may offer a novel therapy for malignant gliomas by reducing cell proliferation, angiogenesis, and motility.
Insights
Small molecule inhibitors targeting the transforming growth factor-beta (TGF-beta) receptor show promise for treating malignant gliomas. SB-431542 effectively reduced glioma cell proliferation, invasion, and angiogenesis in vitro.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Transforming growth factor-beta (TGF-beta) is a key cytokine involved in malignant glioma progression, driving invasion, angiogenesis, and immunosuppression.
- While targeting TGF-beta(2) has shown potential, multiple TGF-beta ligands mediate its effects in gliomas.
Purpose of the Study:
- To investigate the efficacy of SB-431542, a novel small molecule inhibitor of the type I TGF-beta receptor, against human malignant glioma cell lines.
- To determine SB-431542's impact on TGF-beta signaling pathways and downstream effectors critical for glioma growth.
Main Methods:
- Treatment of human malignant glioma cell lines with SB-431542.
- Assessment of SMAD phosphorylation and nuclear translocation.
- Measurement of TGF-beta-mediated transcription, vascular endothelial growth factor (VEGF), and plasminogen activator inhibitor-1 (PAI-1) expression.
- Evaluation of glioma cell proliferation, morphology, and motility.
Main Results:
- SB-431542 effectively blocked SMAD signaling, reducing TGF-beta-mediated transcription.
- The inhibitor decreased the expression of VEGF and PAI-1, crucial TGF-beta effectors.
- SB-431542 inhibited glioma cell proliferation, altered TGF-beta-induced morphology, and reduced cellular motility.
Conclusions:
- Small molecule inhibitors of TGF-beta receptors, such as SB-431542, represent a potential therapeutic strategy for malignant gliomas.
- Targeting the TGF-beta receptor pathway can simultaneously address multiple pro-tumorigenic mechanisms including proliferation, angiogenesis, and invasion.
